Treatment for substance use disorders (SUD) remains low in the United States. To better meet needs of people who use alcohol and other drugs, low threshold bridge clinics which offer treatment without barrier and harm reduction services have gained prevalence. Bridge clinics work to surmount barriers to care by providing same day medication and treatment for SUD and eventually transitioning patients to community-based treatment providers. In this study, we examine SUD treatment outcomes among patients who transitioned out of a bridge clinic.
Methods:
This is a retrospective cohort study of posttreatment outcomes of patients seen at an urban medical center’s bridge clinic between 2017 and 2022. The primary outcome was being in care anywhere at time of follow-up. We also examined the proportion of patients who completed each step of the cascade of care following transfer: connection to transfer clinic, completion of a clinic visit, retention in care, and medication use among those remaining in care at the transfer clinic. We examined the association of different bridge clinic services with still being in care anywhere and the association between successful transfer with being in care and taking medication at follow-up.
Results:
Of 209 eligible participants, 63 were surveyed. Sixty-five percent of participants identified as male, 74% as white, 12% as Hispanic, 6% as Black, and 16% were unhoused. Most participants (78%) reported being connected to SUD treatment from the Bridge Clinic, and 37% remained in care at the same facility at the time of survey. Eighty-four percent reported being in treatment anywhere and 68% reported taking medication for SUD at follow-up, with most participants reporting taking buprenorphine (46%).
Conclusion:
Of those participants who transitioned out of a bridge clinic into community-based SUD care, 78% were successfully connected to ongoing care and 84% were still in care at follow-up.
SpencerMMiniñoAWarnerM.Drug overdose deaths in the United States, 2001–2021. NCHS Data Brief. 2022;457:1-8. doi:10.15620/cdc:122556
2.
WhiteAMCastleIJPPowellPAHingsonRWKoobGF.Alcohol-related deaths during the COVID-19 pandemic. JAMA. 2022;327(17):1704-1706. doi:10.1001/jama.2022.4308
3.
Center for Behavioral Health Statistics and Quality. Key Substance Use and Mental Health Indicators in the United States: results from the 2020 National Survey on Drug Use and Health. (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021. Accessed June 17, 2024. https://www.samhsa.gov/data/
4.
KourounisGRichardsBDWKyprianouESymeonidouEMallioriMMSamartzisL.Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1-8. doi:10.1016/j.drugalcdep.2015.12.021
5.
SimonRSnowRWakemanS.Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study. Subst Abus. 2020;41(4):519-525. doi:10.1080/08897077.2019.1671942
6.
MuncanBWaltersSMEzellJOmpadDC.“they look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1). doi:10.1186/s12954-020-00399-8
7.
PaquetteCESyvertsenJLPolliniRA.Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104-110. doi:10.1016/j.drugpo.2018.04.004
8.
Van BoekelLCBrouwersEPMVan WeeghelJGarretsenHFL.Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1-3):23-35. doi:10.1016/j.drugalcdep.2013.02.018
9.
KrawczykNRiveraBDJentVKeyesKMJonesCMCerdáM.Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786. doi:10.1016/j.drugpo.2022.103786
10.
MaddenEFPrevedelSLightTSulzerSH.Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181-2201. doi:10.1080/10826084.2021.1975749
11.
AronowitzSV.BehrendsCNLowensteinMSchackmanBWeinerJ. Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach. Research Brief, University of Pennsylvania’s Leonard Davis Institute of Health Economics; 2022. Accesses June 17, 2024. Penn-LDI.CHERISH-Issue-Brief.January-2022.pdf (upenn.edu)
GreenfieldLBradybJVBestemanaKJDe SmetaA.Patient Retention in Mobile and Fixed-Site Methadone Maintenance Treatment. Drug Alcohol Depend1996; 42(2): 125-131.
14.
ReganSHowardSPowellE, et al. Emergency department-initiated buprenorphine and referral to follow-up addiction care: a program description. J Addict Med. 2022;16(2):216-222. doi:10.1097/ADM.0000000000000875
15.
WhitesideLKD’OnofrioGFiellinDA, et al. Models for implementing emergency department–initiated buprenorphine with referral for ongoing medication treatment at emergency department discharge in diverse academic centers. Ann Emerg Med2022;80(5):410-419. doi:10.1016/j.annemergmed.2022.05.010
16.
TaylorJLJohnsonSCruzRGrayJRSchiffDBagleySM.Integrating harm reduction into outpatient opioid use disorder treatment settings. J Gen Intern Med. 2021;36(12):3810-3819. doi:10.1007/s11606-021-06904-4
17.
HallGNeighborsCJIheomaJ, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J Subst Abuse Treat. 2014;46(4):511-515. doi:10.1016/j.jsat.2013.11.002
18.
WakemanSEMcGovernSKehoeL, et al. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic. J Subst Abuse Treat. 2022;141:108848. doi:10.1016/j.jsat.2022.108848
19.
TaylorJLWakemanSEWalleyAYKehoeLG.Substance use disorder bridge clinics: models, evidence, and future directions. Addict Sci Clin Pract. 2023;18(1):23. doi:10.1186/s13722-023-00365-2
20.
SnowRLSimonREJackHEOllerDKehoeLWakemanSE.Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic. J Subst Abuse Treat. 2019;107:1-7. doi:10.1016/j.jsat.2019.09.003
21.
SullivanRWSzczesniakLMWojcikSM.Bridge clinic buprenorphine program decreases emergency department visits. J Subst Abuse Treat. 2021;130:108410. doi:10.1016/j.jsat.2021.108410
22.
MartinAButlerKChavezT, et al. Beyond buprenorphine: models of follow-up care for opioid use disorder in the emergeny department. Western J Emerg Med. 2020;21(6):257. doi:10.5811/westjem.2020.7.46079
23.
BraunHMWalterCFarrellNBielloKBTaylorJL.HIV exposure prophylaxis delivery in a low-barrier substance use disorder bridge clinic during a local HIV outbreak at the onset of the COVID-19 pandemic. J Addict Med. 2022;16(6):678-683. doi:10.1097/ADM.0000000000000991
24.
PriceCNSolomonDAJohnsonJAMontgomeryMWMartinBSuzukiJ.Feasibility and safety of outpatient parenteral antimicrobial therapy in conjunction with addiction treatment for people who inject drugs. J Infect Dis. 2020;222(Supplement_5):S494-S498. doi:10.1093/infdis/jiaa025
25.
SnyderHKalminMMMoulinA, et al. Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA bridge program. Ann Emerg Med. 2021;78(6):759-772. doi:10.1016/j.annemergmed.2021.05.024
26.
LaksJKehoeJFarrellNM, et al. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule. Addict Sci Clin Pract. 2021;16(1):73. doi:10.1186/s13722-021-00279-x
27.
WakemanSEKaneMPowellE, et al. A hospital-wide initiative to redesign substance use disorder care: impact on pharmacotherapy initiation. Subst Abus. 2021;42(4):767-774. doi:10.1080/08897077.2020.1846664
28.
WakemanSEMetlayJPChangYHermanGERigottiNA.Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity. J Gen Intern Med. 2017;32(8):909-916. doi:10.1007/s11606-017-4077-z
29.
CheungFLucasRE.Assessing the validity of single-item life satisfaction measures: results from three large samples. Qual Life Res. 2014;23(10):2809-2818. doi:10.1007/s11136-014-0726-4
30.
LangAJWilkinsKRoy-ByrnePP, et al. Abbreviated PTSD Checklist (PCL) as a guide to clinical response. Gen Hosp Psychiatry. 2012;34(4):332-338. doi:10.1016/j.genhosppsych.2012.02.003
31.
HuTMcCormackDJuurlinkDN, et al. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario. CMAJ. 2023;195(49):E1709-E1717. doi:10.1503/cmaj.231014
32.
KimmelSDWalleyAYLiY, et al. Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use-associated infective endocarditis. JAMA Netw Open. 2020;3(10):e2016228. doi:10.1001/jamanetworkopen.2020.16228
33.
JenningsLKLaneSMcCauleyJ, et al. Retention in treatment after emergency department-initiated buprenorphine. J Emerg Med. 2021;61(3):211-221. doi:10.1016/j.jemermed.2021.04.007
ParkJNAgeeTMcCormickS, et al. Retention and overdose risk among patients receiving substance use disorder treatment, mental health care and peer recovery support: a longitudinal analysis. J Addict Med. 17(5):608-611. doi:10.1097/ADM.0000000000001167
36.
SchwartzRPKellySMMitchellSG, et al. Patient-centered methadone treatment: a randomized clinical trial. Addiction. 2017;112(3):454-464. doi:10.1111/add.13622
37.
ParadiseRKDesmaraisJO’MalleySE, et al. Perspectives and recommendations of opioid overdose survivors experiencing unsheltered homelessness on housing, overdose, and substance use treatment in Boston, MA. Int J Drug Policy. 2023;119:104127. doi:10.1016/j.drugpo.2023.104127
38.
GolanOKTotaramRPerryE, et al. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug Alcohol Depend. 2022;235:109445. doi:10.1016/j.drugalcdep.2022.109445
39.
WalleyAYPaasche-OrlowMLeeEC, et al. Acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis. J Addict Med. 2012;6(1):50-56. doi:10.1097/ADM.0b013e318231de51
40.
RamanSRFordCBHammillBGClarkAGCliftonDCJacksonGL.Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study. Addict Sci Clin Pract. 2023;18(1):42. doi:10.1186/s13722-023-00396-9
41.
GopaldasMWenzelKCampbellANC, et al. Impact of medication-based treatment on health care utilization among individuals with opioid use disorder. Psychiatr Serv. 2023;74(12):1227-1233. doi:10.1176/appi.ps.20220549
42.
WakemanSELarochelleMRAmeliO, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
43.
CuppJAByrneKAHerbertKRothPJ.Acute care utilization after recovery coaching linkage during substance-related inpatient admission: results of two randomized controlled trials. J Gen Intern Med. 2022;37(11):2768-2776. doi:10.1007/s11606-021-07360-w
44.
MagidsonJFReganSPowellE, et al. Peer recovery coaches in general medical settings: changes in utilization, treatment engagement, and opioid use. J Subst Abuse Treat. 2021;122:108248. doi:10.1016/j.jsat.2020.108248
45.
WakemanSERigottiNAChangY, et al. Effect of integrating substance use disorder treatment into primary care on inpatient and emergency department utilization. J Gen Intern Med. 2019;34(6):871-877. doi:10.1007/s11606-018-4807-x
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
